Alphatec Holdings, Inc. (NASDAQ:ATEC) Receives Average Rating of “Moderate Buy” from Brokerages

Alphatec Holdings, Inc. (NASDAQ:ATEC) has received a consensus rating of “Moderate Buy” from the nine research firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $17.56.

A number of research analysts have recently issued reports on the stock. HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Alphatec in a research report on Tuesday, January 14th. Barclays raised their price target on shares of Alphatec from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 22nd. Finally, Needham & Company LLC raised their price target on shares of Alphatec from $13.00 to $16.00 and gave the stock a “buy” rating in a research report on Monday, January 13th.

Alphatec Price Performance

ATEC opened at $10.61 on Monday. The company has a fifty day simple moving average of $10.48 and a 200 day simple moving average of $8.24. The firm has a market cap of $1.50 billion, a price-to-earnings ratio of -8.29 and a beta of 1.43. Alphatec has a twelve month low of $4.88 and a twelve month high of $15.69. The company has a current ratio of 2.32, a quick ratio of 1.15 and a debt-to-equity ratio of 30.21.

Insider Buying and Selling

In related news, CEO Patrick Miles sold 50,000 shares of the stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $12.03, for a total value of $601,500.00. Following the sale, the chief executive officer now owns 6,152,544 shares of the company’s stock, valued at $74,015,104.32. This trade represents a 0.81 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP David Sponsel sold 58,283 shares of the stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $10.71, for a total transaction of $624,210.93. Following the completion of the sale, the executive vice president now directly owns 502,311 shares in the company, valued at approximately $5,379,750.81. This trade represents a 10.40 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 222,376 shares of company stock valued at $2,557,148 in the last quarter. Company insiders own 22.80% of the company’s stock.

Hedge Funds Weigh In On Alphatec

Several large investors have recently bought and sold shares of ATEC. Royal Bank of Canada increased its stake in Alphatec by 171.2% during the 4th quarter. Royal Bank of Canada now owns 3,185,283 shares of the medical technology company’s stock valued at $29,240,000 after buying an additional 2,010,806 shares during the period. American Century Companies Inc. increased its stake in Alphatec by 36.5% during the 4th quarter. American Century Companies Inc. now owns 4,989,057 shares of the medical technology company’s stock valued at $45,800,000 after buying an additional 1,334,780 shares during the period. Nuveen Asset Management LLC increased its stake in Alphatec by 78.4% during the 4th quarter. Nuveen Asset Management LLC now owns 2,584,996 shares of the medical technology company’s stock valued at $23,730,000 after buying an additional 1,136,330 shares during the period. Marshall Wace LLP increased its stake in Alphatec by 139.2% during the 4th quarter. Marshall Wace LLP now owns 1,773,246 shares of the medical technology company’s stock valued at $16,278,000 after buying an additional 1,032,070 shares during the period. Finally, Emerald Advisers LLC increased its stake in Alphatec by 112.4% during the 4th quarter. Emerald Advisers LLC now owns 1,456,033 shares of the medical technology company’s stock valued at $13,366,000 after buying an additional 770,586 shares during the period. Institutional investors and hedge funds own 66.35% of the company’s stock.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.